WILMINGTON, Mass., Mar. 26, 2018 /PRNewswire/ — CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ™ vancomycin oral…
